Articles from Inocras Inc.

Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, today announced the signing of a Memorandum of Understanding (MOU) with ChiMei Medical Center (CMMC), a premier medical institution in Taiwan, and Trivator Biomedical Limited, a biomedical advisory firm in Taiwan. This expansion agreement aims to introduce Inocras’s MRDVision tumor-informed minimal residual disease (MRD) test, utilizing circulating tumor DNA (ctDNA) blood samples, and CancerVision, its AI-powered bioinformatics cloud solution, to support WGS at CMMC, advancing Taiwan’s precision oncology landscape.

Today, Inocras announced the signing of a groundbreaking Collaborative Research Agreement with the Center for Data Driven Discovery in Biomedicine (D3b) to advance research into rare sinonasal cancers. Under the agreement, Inocras will conduct Whole Genome Sequencing (WGS) and bioinformatic analysis on rare sinonasal cancer samples provided by D3b.

ANSI ASQ National Accreditation Board (ANAB) has awarded whole genome sequencing and bioinformatics company, Inocras Inc., accreditation to the ISO 15189 standard under its ISO 15189 Medical Laboratories Accreditation Program. Notably, Inocras is one of very few companies in the world with a CAP/CLIA/ISO 15189 accredited lab performing whole genome sequencing for cancer.

Inocras Inc. (Head Office: 6330 Nancy Ridge Drive Suite 106
San Diego, CA 92121, President & CEO: Jehee Suh) (“Inocras”) and Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama) (“SPI”) signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionize healthcare in Japan by leveraging genomic data and bioinformatics to better understand and treat cancer and other genetic conditions.

Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turnaround time, all at a low cost.

Inocras, an industry leader in whole genome sequencing and bioinformatics, released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS). In a head-to-head comparison with Ilumina’s widely-used TSO500, Inocras demonstrated TE-WGS’s ability to match the industry standard for biomarker detection in oncology, while also offering additional insights that enhance clinical understanding.

Inocras Inc., a leader in whole genome sequencing and bioinformatics, announced today that it is now offering whole genome sequencing services using the UG 100TM sequencer from Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput, low cost, next-generation sequencing (NGS) architecture.

Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for cancer patient care. This strategic collaboration leverages Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching, with the shared mission of enhancing personalized care for cancer patients.

Inocras Inc., a leader in whole genome sequencing (WGS) diagnostics and precision medicine, is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S. Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers.

Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.

Inocras, a leading provider of precision healthcare solutions company advancing whole-genome technology, is making an impact at the American Association for Cancer Research (AACR) 2024 annual meeting from April 5 to 10, held in San Diego. This event premieres Inocras's substantial research and pioneering innovation in cancer diagnostics, driven by cutting-edge machine learning technology.

Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.